Literature DB >> 16735485

Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk.

Harald Dobnig1, Jutta Claudia Piswanger-Sölkner, Martin Roth, Barbara Obermayer-Pietsch, Andreas Tiran, Andrea Strele, Elisabeth Maier, Peter Maritschnegg, Christian Sieberer, Astrid Fahrleitner-Pammer.   

Abstract

CONTEXT: Fractures are a major health burden in elderly institutionalized persons. Type 2 diabetes mellitus (DM) has a high prevalence in nursing home patients and has been associated with positive effects on bone mass in younger, community-dwelling elderly.
OBJECTIVE: The objective of this study was to investigate whether type 2 DM affects bone mass, bone turnover, or prospective fracture rates in frail, elderly women living in nursing homes. DESIGN, SETTING, AND PARTICIPANTS: This study was a prospective cohort of 583 patients with type 2 DM and 1081 control (CTR) individuals above age 70 recruited from 95 nursing homes in Austria. Patients were enrolled and followed up by mobile study teams. MAIN OUTCOME MEASURES: We performed quantitative bone ultrasound measurements at the calcaneus, radius, and proximal third phalanx, measurements of quadriceps strength, and biochemical parameters of mineral metabolism and bone turnover. Patients were prospectively followed for hip and other nonvertebral fractures over 2 yr.
RESULTS: Patients with type 2 DM had significantly higher age-, weight-, and mobility score-adjusted calcaneal stiffness (P < 0.0001), radial speed of sound (P < 0.005), and phalangeal speed of sound (P < 0.05) measurements when compared with CTRs. Mean serum PTH (-20.7%) and osteocalcin levels (-22.3%) were significantly lower (both P < 0.0001) in patients with treated type 2 DM despite comparable low serum 25-hydroxyvitamin D levels and slightly higher adjusted total serum calcium levels compared with CTRs. Important independent determinants of bone turnover in both patient groups were PTH, creatinine clearance, alanine aminotransferase, as well as glycosylated hemoglobin levels, together accounting for 30-40% of its variance. A total of 110 hip fractures occurred during the observation period, corresponding to a hip fracture rate of 3.1% (in CTRs) and 3.4% (in type 2 DM) per 100 patient years; this was not significantly different for CTRs and diabetics.
CONCLUSIONS: Decreased PTH levels and higher levels of glycemia independently contribute to lower bone turnover in elderly nursing home patients with type 2 DM. Despite higher bone mass and lower bone turnover, hip fracture risk is comparable with women without DM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735485     DOI: 10.1210/jc.2006-0460

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  64 in total

Review 1.  Bone health and type 2 diabetes mellitus: a systematic review.

Authors:  Erin Gorman; Anna M Chudyk; Kenneth M Madden; Maureen C Ashe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

2.  In vivo assessment of bone quality in postmenopausal women with type 2 diabetes.

Authors:  Joshua N Farr; Matthew T Drake; Shreyasee Amin; L Joseph Melton; Louise K McCready; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

3.  Socioeconomic status, race, and bone turnover in the Midlife in the US Study.

Authors:  C J Crandall; D Miller-Martinez; G A Greendale; N Binkley; T E Seeman; A S Karlamangla
Journal:  Osteoporos Int       Date:  2011-08-03       Impact factor: 4.507

4.  Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients.

Authors:  S Pilz; A Meinitzer; A Tomaschitz; K Kienreich; H Dobnig; M Schwarz; D Wagner; C Drechsler; C Piswanger-Sölkner; W März; A Fahrleitner-Pammer
Journal:  Osteoporos Int       Date:  2012-03-17       Impact factor: 4.507

Review 5.  Childhood obesity, bone development, and cardiometabolic risk factors.

Authors:  Norman K Pollock
Journal:  Mol Cell Endocrinol       Date:  2015-03-27       Impact factor: 4.102

Review 6.  A review of rodent models of type 2 diabetic skeletal fragility.

Authors:  Roberto J Fajardo; Lamya Karim; Virginia I Calley; Mary L Bouxsein
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

7.  Bone metabolism and the 10-year probability of hip fracture and a major osteoporotic fracture using the country-specific FRAX algorithm in men over 50 years of age with type 2 diabetes mellitus: a case-control study.

Authors:  Harjit P Bhattoa; Ugo Onyeka; Edit Kalina; Adam Balogh; Gyorgy Paragh; Peter Antal-Szalmas; Miklos Kaplar
Journal:  Clin Rheumatol       Date:  2013-04-16       Impact factor: 2.980

Review 8.  Diabetes and fractures: an overshadowed association.

Authors:  Natasha B Khazai; George R Beck; Guillermo E Umpierrez
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-12       Impact factor: 3.243

9.  Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis.

Authors:  Joyce B J van Meurs; Thomas A Trikalinos; Stuart H Ralston; Susana Balcells; Maria Luisa Brandi; Kim Brixen; Douglas P Kiel; Bente L Langdahl; Paul Lips; Osten Ljunggren; Roman Lorenc; Barbara Obermayer-Pietsch; Claes Ohlsson; Ulrika Pettersson; David M Reid; Francois Rousseau; Serena Scollen; Wim Van Hul; Lidia Agueda; Kristina Akesson; Lidia I Benevolenskaya; Serge L Ferrari; Göran Hallmans; Albert Hofman; Lise Bjerre Husted; Marcin Kruk; Stephen Kaptoge; David Karasik; Magnus K Karlsson; Mattias Lorentzon; Laura Masi; Fiona E A McGuigan; Dan Mellström; Leif Mosekilde; Xavier Nogues; Huibert A P Pols; Jonathan Reeve; Wilfried Renner; Fernando Rivadeneira; Natasja M van Schoor; Kurt Weber; John P A Ioannidis; André G Uitterlinden
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

Review 10.  Integrative physiology: defined novel metabolic roles of osteocalcin.

Authors:  Yu-Sik Kim; Il-Young Paik; Young-Jun Rhie; Sang-Hoon Suh
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.